Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has announced its participation in the Cantor 2026 Global Healthcare Conference, scheduled to take place from September 9-11, 2026, in New York. The company's management team, including President and CEO Seth Lederman, M.D., will engage in a fireside chat and one-on-one meetings with investors. Dr. Lederman's presentation is set for September 10 from 3:55-4:25 p.m. ET, and a live webcast and replay will be accessible through the Investors section of the Tonix website.
This appearance is significant as it provides a platform for Tonix to communicate its strategic initiatives and recent milestones to a broad investment audience. Tonix is a fully integrated, commercial-stage biotechnology company concentrating on central nervous system (CNS) and immunology treatments for areas with high unmet medical needs. The company recently achieved a major milestone with the approval of TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in over 15 years. This approval marks Tonix's entry into the commercial stage, and the company is now leveraging its CNS commercial infrastructure to support TONMYA and its acute migraine products, Zembrace SymTouch and Tosymra.
Beyond TONMYA, Tonix is actively advancing a robust pipeline designed to address significant therapeutic gaps. The company is conducting Phase 2 clinical trials to evaluate TONMYA's potential in treating major depressive disorder and acute stress disorder, which could expand its indications and market potential. Additionally, Tonix's CNS portfolio includes TNX-2900, a Phase 2-ready candidate for Prader-Willi syndrome, a rare genetic disorder with no approved treatments. In the immunology space, Tonix is developing TNX-4800, a monoclonal antibody for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor aimed at preventing kidney transplant rejection. These programs underscore Tonix's commitment to addressing complex diseases with high morbidity and limited therapeutic options.
The company's participation in the Cantor conference comes at a pivotal time as it seeks to communicate its growth strategy and the potential of its pipeline. Investors will likely be keen to hear updates on commercial launch progress for TONMYA, enrollment in ongoing trials, and any upcoming catalysts. The conference also serves as an opportunity for Tonix to engage with analysts and institutional investors, potentially enhancing its visibility in the financial community. For more information about Tonix Pharmaceuticals, visit the company's newsroom at https://nnw.fm/TNXP.
